>_ QFI Terminal
Terminal › Stocks › ABBV

AbbVie Inc. (ABBV) Stock

Healthcare · Drug Manufacturers - General · US
$294.98 +0.37%
Last updated Nov 12, 2026 09:20 UTC

ABBV Key Statistics

Market Cap$521.27B
P/E (TTM)50.77
P/S (TTM)7.90
P/B (TTM)-114.99
Revenue (TTM)$66.01B
EPS (TTM)$5.81
Dividend Yield2.96%
ROE (TTM)-202.50%
Net Margin15.67%
Gross Margin73.72%
52W High$302.93
52W Low$190.75
Analyst ViewBuy
Price Target$308.88
Employees57,000
Volume3,177,657

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

CEO: Robert A. Michael. Company website

ABBV — Frequently Asked Questions

What is the ABBV stock price today?

AbbVie Inc. (ABBV) trades at $294.98, up 0.37% on the day, as of Nov 12, 2026 09:20 UTC.

What is AbbVie Inc.'s market cap?

AbbVie Inc. has a market capitalisation of $521.27B, calculated from the live ABBV share price and shares outstanding.

What is the P/E ratio of ABBV?

ABBV trades at a trailing P/E of 50.77, from earnings per share of $5.81 over the last twelve months.

How much revenue does AbbVie Inc. make?

AbbVie Inc. generated revenue of $66.01B over the trailing twelve months, which puts the stock at 7.90 times sales.

Does ABBV pay a dividend?

Yes. AbbVie Inc. pays a dividend yielding 2.96% on the current share price.

What is the 52-week range for ABBV?

ABBV has traded between $190.75 and $302.93 over the past 52 weeks, and the last price is 2.6% below that high.

Is AbbVie Inc. profitable?

Yes. AbbVie Inc. keeps 15.67% of revenue as net income over the trailing twelve months.

What is the analyst price target for ABBV?

Wall Street analysts rate ABBV Buy, with an average price target of $308.88, 4.7% above the current price.

What sector is AbbVie Inc. in?

AbbVie Inc. is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in US.

Who is the CEO of AbbVie Inc.?

Robert A. Michael is the chief executive of AbbVie Inc., which employs 57,000 people.

Where can I track ABBV in real time?

QFI Terminal shows ABBV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See ABBV live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open ABBV in Terminal See plans

Drug Manufacturers - General stocks

NVO Novo Nordisk A/S JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck & Co., Inc. PFE Pfizer Inc. AZN AstraZeneca PLC NVS Novartis AG SNY Sanofi BMY Bristol-Myers Squibb Company AMGN Amgen Inc. GSK GSK plc GILD Gilead Sciences, Inc. BIIB Biogen Inc. OGN Organon & Co. SCLX Scilex Holding Company

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. HCA HCA Healthcare, Inc. ABT Abbott Laboratories TMO Thermo Fisher Scientific Inc. MOH Molina Healthcare, Inc. MDT Medtronic Plc MDLN Medline Inc. SYK Stryker Corporation DHR Danaher Corporation THC Tenet Healthcare Corporation GEHC GE HealthCare Technologies Inc. BSX Boston Scientific Corporation BDX Becton, Dickinson and Company FMS Fresenius Medical Care AG & Co. KGaA UHS Universal Health Services, Inc. OSCR Oscar Health, Inc. IQV IQVIA Holdings Inc.

ETFs holding ABBV

XLV State Street Health Care Select Sector SPDR ETF 7.59% HDV iShares Core High Dividend ETF 6.78% DGRO iShares Core Dividend Growth ETF 3.01% DGRW WisdomTree U.S. Quality Dividend Growth Fund 2.36% VIG Vanguard Dividend Appreciation ETF 2.05% VYM Vanguard High Dividend Yield ETF 1.96% VTV Vanguard Morningstar Value ETF 1.75% SCHV Schwab U.S. Large-Cap Value ETF 1.70% XBI State Street SPDR S&P Biotech ETF 1.69% INFO Harbor PanAgora Dynamic Large Cap Core ETF 1.57% NOBL ProShares - S&P 500 Dividend Aristocrats ETF 1.42% IWD iShares Russell 1000 Value ETF 1.24% SDY State Street SPDR S&P Dividend ETF 1.17% IVV iShares Core S&P 500 ETF 0.80% USMV iShares MSCI USA Min Vol Factor ETF 0.80% SPY State Street SPDR S&P 500 ETF 0.80% SCHX Schwab U.S. Large-Cap ETF 0.76% IWB iShares Russell 1000 ETF 0.74% FNDX Schwab Fundamental U.S. Large Company ETF 0.73% FB ProShares S&P 500 Dynamic Buffer ETF 0.73% SCHB Schwab U.S. Broad Market ETF 0.72% VOO Vanguard S&P 500 ETF 0.70% VTI Vanguard Morningstar Total Stock Market ETF 0.63% ACWI iShares MSCI ACWI ETF 0.51% UPRO ProShares - UltraPro S&P500 0.45% VT Vanguard Total World Stock ETF 0.39% RSP Invesco S&P 500 Equal Weight ETF 0.23% SPXL Direxion Daily S&P 500 Bull 3X Shares 0.17% IWF iShares Russell 1000 Growth ETF 0.14%

Largest institutional holders of ABBV

BlackRock, Inc. BLK 149,488,412 shares
VANGUARD CAPITAL MANAGEMENT LLC 115,396,098 shares
STATE STREET CORP STT 82,596,748 shares
VANGUARD PORTFOLIO MANAGEMENT LLC 48,477,996 shares
JPMORGAN CHASE & CO JPM 47,862,796 shares
GEODE CAPITAL MANAGEMENT, LLC 47,503,777 shares
MORGAN STANLEY MS 38,901,001 shares
Capital Research Global Investors 30,101,551 shares
NORGES BANK 25,554,538 shares
BANK OF AMERICA CORP /DE/ BAC 21,237,764 shares

ABBV insiders on other boards

UAL United Airlines Holdings, Inc. Hart Brett J FRSH Freshworks Inc. Austin Roxanne S CRWD CrowdStrike Holdings, Inc. Austin Roxanne S ENTG Entegris, Inc. Saleki-gerhardt Azita ABT Abbott Laboratories Alpern Robert J VZ Verizon Communications Inc. Austin Roxanne S IBM International Business Machines Corporation Waddell Frederick H LMT Lockheed Martin Corporation Falk Thomas J PSX Phillips 66 Tilton Glenn F PG The Procter & Gamble Company Davis Jennifer L.